Literature DB >> 34020034

The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients.

S Street1, D Chute2, I Strohbehn2, S Zhao2, M Rengarajan3, A Faje3, H Seethapathy2, M Lee2, R Seethapathy2, Z Drobni4, O Rahma5, T G Neilan6, R J Sullivan6, A C Villani7, L Zubiri8, M J Mooradian8, K L Reynolds8, M E Sise9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34020034      PMCID： PMC8814352          DOI： 10.1016/j.annonc.2021.05.357

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   51.769


× No keyword cloud information.
  6 in total

1.  Immortal time bias in observational studies of drug effects.

Authors:  Samy Suissa
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-03       Impact factor: 2.890

2.  Challenges of guarantee-time bias.

Authors:  Anita Giobbie-Hurder; Richard D Gelber; Meredith M Regan
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

3.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J B A G Haanen; F Carbonnel; C Robert; K M Kerr; S Peters; J Larkin; K Jordan
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

4.  Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.

Authors:  Ichiro Yamauchi; Akihiro Yasoda; Shigemi Matsumoto; Yuichi Sakamori; Young Hak Kim; Motoo Nomura; Atsushi Otsuka; Toshinari Yamasaki; Ryoichi Saito; Morimasa Kitamura; Toshio Kitawaki; Masakatsu Hishizawa; Nobuko Kawaguchi-Sakita; Toshihito Fujii; Daisuke Taura; Masakatsu Sone; Nobuya Inagaki
Journal:  PLoS One       Date:  2019-05-14       Impact factor: 3.240

5.  Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.

Authors:  Xiaoxiang Zhou; Zhuoran Yao; Huaxia Yang; Naixin Liang; Xuan Zhang; Fengchun Zhang
Journal:  BMC Med       Date:  2020-04-20       Impact factor: 8.775

Review 6.  Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.

Authors:  Satya Das; Douglas B Johnson
Journal:  J Immunother Cancer       Date:  2019-11-15       Impact factor: 13.751
  6 in total
  10 in total

1.  Immune Checkpoint Inhibitor-related Endocrinopathies.

Authors:  Difei Lu; Ying Gao
Journal:  J Transl Int Med       Date:  2022-04-02

Review 2.  Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.

Authors:  Yee-Ming Melody Cheung; Wei Wang; Bradley McGregor; Ole-Petter Riksfjord Hamnvik
Journal:  Cancer Immunol Immunother       Date:  2022-01-13       Impact factor: 6.630

3.  Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.

Authors:  Difei Lu; Jun Yao; Geheng Yuan; Ying Gao; Junqing Zhang; Xiaohui Guo
Journal:  Oncologist       Date:  2022-03-04       Impact factor: 5.837

4.  Immune checkpoint inhibitor-induced thyroiditis is a risk factor for acute and chronic kidney dysfunction.

Authors:  Ian A Strohbehn; Sarah Street; Donald Chute; Harish Seethapathy; Meghan Lee; Rituvanthikaa Seethapathy; Zsofia D Drobni; Osama Rahma; Tomas G Neilan; Leyre Zubiri; Kerry Reynolds; Meghan E Sise
Journal:  Nephrol Dial Transplant       Date:  2021-12-31       Impact factor: 7.186

Review 5.  Immune-checkpoint inhibitors: long-term implications of toxicity.

Authors:  Douglas B Johnson; Caroline A Nebhan; Javid J Moslehi; Justin M Balko
Journal:  Nat Rev Clin Oncol       Date:  2022-01-26       Impact factor: 65.011

6.  Immune-Related Thyroiditis as a Predictor for Survival in Metastatic Renal Cell Carcinoma.

Authors:  Shira Sagie; Moran Gadot; Meital Levartovsky; Hadas Gantz Sorotsky; Raanan Berger; Michal Sarfaty; Ruth Percik
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

Review 7.  Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management.

Authors:  Harish Seethapathy; Sandra M Herrmann; Meghan E Sise
Journal:  Kidney Med       Date:  2021-10-08

8.  Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.

Authors:  Xiaohong Xie; Liqiang Wang; Yingqing Li; Yan Xu; Jianhui Wu; Xinqing Lin; Wen Lin; Qicong Mai; Zhanhong Chen; Jiexia Zhang; Zhanhong Xie; Yinyin Qin; Ming Liu; Mingjun Lu; Bihui Luo; Chengzhi Zhou
Journal:  Front Immunol       Date:  2022-07-18       Impact factor: 8.786

Review 9.  Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy.

Authors:  Adrian Chye; India Allen; Megan Barnet; Deborah L Burnett
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

10.  Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.

Authors:  Jia Luo; Victoria L Martucci; Alexander Gusev; Melinda C Aldrich; Matthew D Hellmann; Elad Ziv; Zoe Quandt; Stefan Groha; Megan H Murray; Christine M Lovly; Hira Rizvi; Jacklynn V Egger; Andrew J Plodkowski; Mohsen Abu-Akeel; Isabell Schulze; Taha Merghoub; Eduardo Cardenas; Scott Huntsman; Min Li; Donglei Hu; Matthew A Gubens
Journal:  Clin Cancer Res       Date:  2021-07-08       Impact factor: 12.531
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.